Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birelentinib + R-CHOP in newly diagnosed DLBCL
NCT07712588Phase 3Not yet recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Sep 2026
- Primary completion
- Jan 2031
- Countries
- 1
01
Overview
A Phase 3 trial of birelentinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
birelentinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07712588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07712588.